NCT04172454View on ClinicalTrials.gov

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

June 17, 2021

Study Completion Date

September 23, 2022

Conditions
Advanced Solid TumorsMelanoma
Interventions
BIOLOGICAL

AK104

AK104, 6mg/kg, Q2W

Trial Locations (1)

510030

Sun Yat-Sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Akeso

INDUSTRY